Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Dec 03, 2020
Agenus to fulfill FDA feedback for six-month follow-up on late responders LEXINGTON, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to
Nov 25, 2020
LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr.
Nov 10, 2020
$10M milestone payment from Merck triggered Agenus is eligible for up to an additional $85 million in milestones plus royalties on sales LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies,
Nov 05, 2020
Immunotherapy Pioneer to Join As Company Ramps Up Commercialization and NextGen Clinical Pipeline Efforts LEXINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and
Nov 02, 2020
Allogeneic (off the shelf) iNKT cell therapy targets patients with moderate to severe COVID-19 iNKT cells designed to clear SARS-CoV-2 virus while reducing harmful inflammation LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an